Integrins, a family of heterodimeric adhesion receptors for various extracellular matrices, have repeatedly been linked to being important initiators and promoters of ovarian cancer growth and progression. Aggressive ovarian tumors exhibit significantly elevated levels of several RGD-based integrin family members, including integrins 5-1 and v3 or v5. These adhesion receptors appear to encourage cell adhesion, survival, motility, and invasion during the development of an ovarian tumor or the spread of its metastatic disease. Notably, the activation of FAK and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways, is crucial for the functions of these integrins.
Transmembrane proteins called integrins serve as important receptors for cell-extracellular matrix (ECM) and cell-cell adhesion.These molecules can be modified, and the v integrin family in particular, has shown to have significant effects on fibrosis in a variety of organs and disease states. According to numerous studies, the latent transforming growth factor (TGF)- is activated by the integrins v3, v5, v6, and v8 in pre-clinical fibrosis models, modulating the fibrotic process.
One of the 18 different types of subunits that are known to exist and one of the eight different types of subunits that are known to exist are typically non-covalently paired to form each integrin. There are currently 24 different heterodimers in total. The fact that the v subunit can form heterodimers with the 1, 3, 5, 6 or 8 subunits and that the 1 subunit can associate with a wide variety of subunits from 1 to 11 shows that not all theoretically possible and subunit pairs form. It's intriguing to note that a variety of v integrins appear to share a common function in TGF- activation.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V10031 | Eptifibatide (free base) | 188627-80-7 | Eptifibatide is a potent glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; Kd = 120 nM) that inhibits platelet aggregation. |
|
V52112 | Eptifibatide monoacetate | 1248559-53-6 | Eptifibatide monoacetate is a cyclic heptapeptide, a glycoprotein IIb/IIIa receptor blocker/inhibitor, and has antiplatelet activity. |
|
V56042 | Etaracizumab (LM 609; MEDI 523; Anti-αvβ3 Integrin Recombinant Antibody) | 892553-42-3 | Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody (mAb). |
|
V34693 | Fibronectin | 86088-83-7 | Fibronectin is a glycoprotein (~500 kDa) found in blood and cells and is a biomarker of tissue damage. |
|
V2856 | Firategrast(SB-683699) | 402567-16-2 | Firategrast (formerly SB683699; T0047; SB-683699; T-0047) is a novel, potent and orally bioavailable alpha4 beta1/alpha4 beta7 (α4β1/α4β7) integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system (CNS). |
|
V56056 | FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro | 2022956-44-9 | FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro is GRGDSP coupled to FITC . |
|
V77000 | Fradafiban hydrochloride (BIBU-52 hydrochloride) | Fradafiban (BIBU-52) HCl is a non-peptide platelet glycoprotein IIb/IIIa complex antagonist that binds to the human platelet GP IIb/IIIa complex with a Kd of 148 nM. | |
|
V52076 | Fuzapladib sodium (IS-741 sodium) | 141284-73-3 | Fuzapladib (IS-741) sodium is an orally bioactive leukocyte function-associated antigen type 1 (LFA-1) activation inhibitor, a leukocyte adhesion molecule. |
|
V56046 | Galacto-RGD | 922175-70-0 | Galacto-RGD is an RGD analog that can be coupled to the radioactive isotope 18F and used as an α₅β₃ integrin-selective tracer. |
|
V21632 | GLPG0187 | 1320346-97-1 | GLPG0187 (GLPG-0187) is a novel, potent, broad spectrum and small molecule integrin receptor antagonist (IRA) with potential anticancer activity, inhibiting αvβ1-integrin with an IC50 of 1.3 nM. |
|
V56049 | Gly-Arg-Gly-Asp-Ser TFA (GRGDS TFA) | 2828433-23-2 | Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of the glycoprotein osteopontin. |
|
V76961 | GRGDSP TFA | GRGDSP (TFA) is an integrin inhibitor. | |
|
V27085 | HSDVHK-NH2 | 848644-86-0 | HSDVHK-NH2 is an inhibitor (blocker/antagonist) of the integrin αvβ3-vitreous binding protein interaction with IC50 of 1.74 pg/mL (2.414 pM). |
|
V80311 | HSDVHK-NH2 TFA | HSDVHK-NH2 TFA is an antagonist of the integrin αvβ3-vitreous binding protein interaction with IC50 of 1.74 pg/mL (2.414 pM). | |
|
V53238 | Integrin Binding Peptide | 278792-07-7 | Integrin Binding Peptide is developed from fibronectin. |
|
V51946 | Integrin modulator 1 | 2023788-32-9 | Integrin modulator 1 is a potent and specific α4β1 integrin agonist/activator with IC50 of 9.8 nM. |
|
V56043 | Integrin-IN-2 | 2378617-67-3 | Integrin-IN-2 is an orally bioavailable pan-αv integrin (αv integrin) inhibitor. |
|
V33012 | iRGD peptide TFA salt | 1392278-76-0 | iRGD peptide(sequence: CRGDKGPDC) is a 9-amino acid cyclic peptide, and a molecular mimicry agent that was originally identified in an in vivo screening of phage display libraries in tumor-bearing mice. |
|
V56050 | KGDS | 93674-95-4 | KGDS is a synthetic peptide that targets integrin GPIIb-IIIa on the cell membrane of human activated platelets. |
|
V51875 | LDV | 1155866-55-9 | LDV is a tripeptide and non-fluorescent analog of LDV-FITC. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
